Poxvirus Purification Process Retaining Extracellular Enveloped Viruses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current poxvirus purification processes primarily focus on intracellular mature virus (IMV) particles, discarding extracellular enveloped virus (EEV) particles, despite EEVs potentially offering greater therapeutic and prophylactic efficacy due to their additional surface proteins, which could provide targeted infection specificity and enhanced therapeutic effects.
Innovation Solution
A process for producing and purifying recombinant poxviruses, specifically extracellular enveloped viruses (EEVs) with no targeted infection specificity, using a combination of depth filtration, microfiltration, and diafiltration to obtain high-titer EEV compositions free from animal-derived products, thereby overcoming the limitations of existing methods that rely on animal-derived compounds and fail to retain EEVs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current poxvirus purification processes focus on IMV particles, then IMV purification efficiency is improved, but EEV particles are discarded despite their potential therapeutic efficacy
Solution Approach 1:
The purification process is segmented into multiple sequential filtration steps (depth filtration, microfiltration, diafiltration) that separately address different purification needs, allowing selective retention of EEV particles while removing contaminants
Solution Approach 2:
The process changes physical parameters (filtration pore sizes, pressure gradients, buffer compositions) across different stages to optimize for EEV retention rather than IMV purification, transforming the purification approach from IMV-focused to EEV-preserving
2Device complexity
If traditional purification methods are used, then process simplicity is maintained, but animal-derived products remain in the final composition
Solution Approach 1:
The process extracts and removes animal-derived contaminants through sequential filtration steps, taking out harmful substances while preserving the therapeutic EEV particles
Solution Approach 2:
The method uses disposable filtration membranes and single-use filtration cassettes that can be discarded after one use, eliminating the need for extensive sterilization and validation procedures while ensuring removal of animal-derived products
3Reliability
If EEV particles are retained in the composition, then therapeutic efficacy is enhanced, but purification process complexity increases
Solution Approach 1:
The filtration system performs multiple functions simultaneously: depth filtration removes large particulates, microfiltration retains EEV particles while allowing buffer exchange, and diafiltration removes contaminants - all within a unified process framework
Solution Approach 2:
The process performs preliminary concentration and clarification steps before the main purification phase, preparing the sample in advance to facilitate easier and more efficient EEV retention during subsequent filtration steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process yields a high-titer EEV composition with enhanced therapeutic and prophylactic efficacy, as demonstrated by improved survival rates and tumor regression in animal models, showcasing the potential of EEVs in cancer treatment and other therapeutic applications.
Implementation Method 1
The culture media and the packaging cells are subjected to a depth filtration step, allowing the withdrawal of the cellular debris
Implementation Method 2
The virus-containing filtrate is then subjected to a microfiltration step, allowing the concentration of the poxviruses
Implementation Method 3
The poxviruses are then purified by subjecting the concentrated virus to a diafiltration step
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.